Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule PURPOSE: Platinum-based ...
PURPOSE: We conducted this randomized study comparing the activity and toxicity of paclitaxel and gemcitabine (PG) and paclitaxel and carboplatin (PC) combinations for the treatment of advanced ...
At its May 30 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) endorsed the approval of several cancer therapies. The drug review panel ...
Immunotherapy improved overall survival when added to cisplatin-gemcitabine but not when added to carboplatin-gemcitabine. Adding immunotherapy to platinum-gemcitabine chemotherapy can improve ...
Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...
Camrelizumab with carboplatin and nab-paclitaxel shows potential as a first-line treatment for ES-SCLC, with promising survival rates. The study identified biomarkers, including MUC17 alterations and ...
Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study evaluating nadunolimab in triple-negative breast cancer (TNBC). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback